Cipla Q1 FY26 Results, Strong EBITDA Margin At 25.6%, PAT Grows 10% YoY

Key Highlights:

- EBITDA margin steady at 25.6 percent, PAT up 10 percent YoY.

- India business crossed Rs 3,000 Cr for first time in Q1.

- Strong performance in Africa; US business stable at USD 226 Mn.

Mumbai: Cipla started FY26 on a strong note with a 4 percent year-on-year (YoY) rise in income from operations at Rs 6,957 crore in Q1 FY26. Profit after tax (PAT) rose 10 percent YoY to Rs 1,298 crore. The company maintained a steady EBITDA margin at 25.6 percent, indicating strong cost controls and operational efficiency.

India Business Reaches New High

Cipla’s One-India business saw a 6 percent YoY growth, touching Rs 3,070 crore—the highest ever for a Q1. The Branded Prescription segment saw fast growth in chronic therapies like Respiratory, Urology, Cardiac, Anti-diabetes, and Anti-infectives. Cipla launched Voltido Trio, adding to its respiratory portfolio.

The Trade Generics segment also performed well, launching 7 new products including ones in Orthopaedics. Consumer Health brands like Nicotex and Omnigel held their leadership positions.

North America Performance Steady

The North America business recorded USD 226 million in revenue, supported by differentiated assets. Cipla launched Nano Paclitaxel vials and Nilotinib Capsules, strengthening its oncology and complex generics pipeline. Albuterol maintained the No.1 market position with a 19.5 percent share, while Lanreotide reached 21 percent.

A new strategic deal was signed to launch Cipla’s first biosimilar in the US by Q2 FY26.

Africa and Other Global Markets Grow Well

The One Africa region grew 11 percent in USD terms, led by strong performance in the private market. Cipla is now ranked No. 2 in the South African prescription market.

Emerging Markets and Europe posted 8 percent growth in USD terms. Both DTM and B2B segments contributed, with solid margins.

Strong Cash Position and Investment in R&D

Cipla had a net cash balance of Rs 10,379 crore as of June 2025. R&D investments were at Rs 432 crore (6.2 percent of sales), reflecting focus on pipeline development and filings.

Cipla remains focused on expanding core markets, strengthening flagship brands, and pushing innovation through R&D for sustained growth.